Document is current

Any future updates will be listed below

A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN study

Crossref DOI link: https://doi.org/10.1007/s10549-016-4033-3

Published Online: 2016-10-31

Published Print: 2017-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark